141 related articles for article (PubMed ID: 36261691)
1. Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer.
Mekdad N; Tran TMH; Desjardins R; Kwiatkowska A; Couture F; Day R
Sci Rep; 2022 Oct; 12(1):17489. PubMed ID: 36261691
[TBL] [Abstract][Full Text] [Related]
2. PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer.
Couture F; Wang L; Dufour F; Chabot-Maheux K; Ekindi Ndongo N; Sabbagh R; Day R
Sci Rep; 2022 Apr; 12(1):6066. PubMed ID: 35410344
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.
Castanares MA; Copeland BT; Chowdhury WH; Liu MM; Rodriguez R; Pomper MG; Lupold SE; Foss CA
Prostate; 2016 Feb; 76(2):215-25. PubMed ID: 26499105
[TBL] [Abstract][Full Text] [Related]
4. PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.
Couture F; Levesque C; Dumulon-Perreault V; Ait-Mohand S; D'Anjou F; Day R; Guérin B
Neoplasia; 2014 Aug; 16(8):634-43. PubMed ID: 25220591
[TBL] [Abstract][Full Text] [Related]
5. Role of proprotein convertases in prostate cancer progression.
Couture F; D'Anjou F; Desjardins R; Boudreau F; Day R
Neoplasia; 2012 Nov; 14(11):1032-42. PubMed ID: 23226097
[TBL] [Abstract][Full Text] [Related]
6. PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.
Panet F; Couture F; Kwiatkowska A; Desjardins R; Guérin B; Day R
Eur J Cell Biol; 2017 Aug; 96(5):469-475. PubMed ID: 28347547
[TBL] [Abstract][Full Text] [Related]
7. PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
Couture F; Sabbagh R; Kwiatkowska A; Desjardins R; Guay SP; Bouchard L; Day R
Cancer Res; 2017 Dec; 77(24):6863-6879. PubMed ID: 28993410
[TBL] [Abstract][Full Text] [Related]
8. Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.
Kwiatkowska A; Couture F; Ait-Mohand S; Desjardins R; Dory YL; Guérin B; Day R
Sci Rep; 2019 Feb; 9(1):2118. PubMed ID: 30765725
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors.
Bakrania A; Aubé M; Desjardins R; Sabbagh R; Day R
Can J Physiol Pharmacol; 2020 Jul; 98(7):477-481. PubMed ID: 32119574
[TBL] [Abstract][Full Text] [Related]
10. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
11. PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.
Levesque C; Couture F; Kwiatkowska A; Desjardins R; Guérin B; Neugebauer WA; Day R
Oncotarget; 2015 Feb; 6(6):3680-93. PubMed ID: 25682874
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of PACE4 isoforms as biomarkers in thyroid cancer.
Fradet L; Temmar R; Couture F; Belzile M; Fortier PH; Day R
J Otolaryngol Head Neck Surg; 2018 Oct; 47(1):63. PubMed ID: 30340539
[TBL] [Abstract][Full Text] [Related]
13. miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway.
Kang S; Zhao Y; Hu K; Xu C; Wang L; Liu J; Yao A; Zhang H; Cao F
Prostate; 2014 Aug; 74(11):1095-106. PubMed ID: 24913567
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of androgenic Chinese herbal medicines on androgen receptors and tumor growth in experimental prostate cancer models.
Zhang ZB; Ip SP; Cho WC; Hu Z; Huang YF; Luo DD; Xian YF; Lin ZX
J Ethnopharmacol; 2020 Oct; 260():113058. PubMed ID: 32525068
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
17. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
Umekita Y; Hiipakka RA; Kokontis JM; Liao S
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218
[TBL] [Abstract][Full Text] [Related]
18. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
[TBL] [Abstract][Full Text] [Related]
19. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J
Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759
[TBL] [Abstract][Full Text] [Related]
20. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
